Skip to main content
  • The Academy has a profound duty to its members, the larger medical community and the public to ensure the integrity of all of its scientific, educational, advocacy and consumer information activities and materials. Thus each Academy Trustee, Secretary, committee Chair, committee member, taskforce chair, taskforce member, councilor, and representative to other organizations (“Academy Leader”), as well as the Academy staff and those responsible for organizing and presenting CME activities must disclose interactions with Companies and manage conflicts of interest or the appearance of conflicts of interest that affect this integrity. Where such conflicts or perceived conflicts exist, they must be appropriately and fully disclosed and mitigated.

    All contributors to Academy educational and leadership activities must disclose all financial relationships (defined below) to the Academy annually. The ACCME requires the Academy to disclose the following to participants prior to the activity:

    • All financial relationships with Commercial Companies that contributors have had within the pre¬vious 24 months. A commercial company is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.
    • Meeting presenters, authors, contributors or reviewers who report they have no known financial relationships to disclose.

    The Academy will request disclosure information from meeting presenters, authors, contributors or reviewers, committee members, Board of Trustees, and others involved in Academy leadership activities (“Contributors”) annually. Disclosure information will be kept on file and used during the calendar year in which it was collected for all Academy activities. Updates to the disclosure information file should be made whenever there is a change. At the time of submission of a Journal article or materials for an educational activity or nomination to a leadership position, each Contributor should specifically review his/her statement on file and notify the Academy of any changes to his/her financial disclosures. These requirements apply to relationships that are in place at the time of or were in place 24 months preceding the presentation, publication submission, or nomination to a leadership position. Any financial relationship that may constitute a conflict of interest will be mitigated prior to the delivery of the activity.

    Financial Relationship Disclosure

    For purposes of this disclosure, a known financial relationship is defined as any financial gain or expectancy of financial gain brought to the Contributor by:

    • Direct or indirect compensation;
    • Ownership of stock in the producing company;
    • Stock options and/or warrants in the producing company, even if they have not been exercised or they are not currently exercisable;
    • Financial support or funding to the investigator, including research support from government agencies (e.g., NIH), device manufacturers, and\or pharmaceutical companies.

    Description of Financial Interests

    Code Description
    C Consultant/Advisor
    Consultant fee, paid advisory boards, or fees for attending a meeting.
    E Employee
    Hired to work for compensation or received a W2 from a company.
    L Lecture Fees/Speakers Bureau
    Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
    P Patents/Royalty 
    Beneficiary of patents and/or royalties for intellectual property.
    S Grant Support 
    Grant support or other financial support from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies. Research funding should be disclosed by the principal or named investigator even if your institution receives the grant and manages the funds.
    EE Employee, Executive Role 
    Hired to work in an executive role for compensation or received a W2 from a company.
    EO Owner of Company 
    Ownership or controlling interest in a company, other than stock.
    SO Stock Options
    Stock options in a private or public company.
    PS Equity/Stock Holder - Private Corp (not listed on the stock exchange)
    Equity ownership or stock in privately owned firms, excluding mutual funds.
    US Equity/Stock Holder - Public Corp  (listed on the stock exchange)
    Equity ownership or stock in publicly traded firms, excluding mutual funds.
    I Independent Contractor 
    Contracted work, including contracted research

    Disclosure list contains individual’s relevant disclosures with ineligible companies. All relevant financial relationships have been mitigated.

    Secretary for Annual Meeting

    Name Disclosure
    Maria M Aaron MD None

    Annual Meeting Program Committee

    The Annual Meeting Program Committee is responsible for the Academy's annual meeting Scientific Program, including Instruction Courses, Symposia, the Spotlight on Cataract, Scientific Papers/Posters and Videos. Each subcommittee has five - ten reviewers who grade the instruction courses and paper/poster abstracts as well as three subcommittee members who review the grades, then select the courses and abstracts for presentation.

    Associate Secretary for the Annual Meeting Program Disclosure
    Bennie H Jeng MD EyeGate Pharmaceuticals Inc.: O; GlaxoSmithKline: C; Kedrion: C; Merck & Co., Inc.: C; Oyster point: C; Sanofi: C
    Annual Meeting Program Committee
    Nicole R Fram MD Alcon Laboratories, Inc.: C; Avellino Labs: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,L,SO; Glaukos Corporation: L; Johnson & Johnson Vision: L,C; LENSAR: C; Ocular Science: SO,C; Ocular Therapeutix: S; Orasis Pharmaceuticals: C,SO; OysterPoint: C; RxSight: L,C; Vital Tears: L; Zeiss: C,L,S
    Jessica B Ciralsky MD NONE
    Paula Anne Newman-Casey MD NONE
    Andrew G Lee MD Horizon: C
    Jonathan W Kim MD NONE
    Martha P Schatz MD NONE
    Elizabeth Yeu MD Advanced Vision Group: C; Alcon Laboratories, Inc.: C,L; Allergan, Inc.: C,L; Aurion: C; Bausch + Lomb: C; Bio-Tissue, Inc.: C,L; BlephEX, LLC: C; Bruder Healthcare Company: C; BVI: C; Carl Zeiss Meditec: C,L; CorneaGen: C; Dompe: C; Expert Opinion: C; Glaukos Corporation: C,L; Johnson & Johnson Vision: C,L; Kala Pharmaceuticals, Inc.: C,S; Katena Products, Inc: C; LENSAR: C; Melt: C; Novartis Pharma AG: C; OCuSOFT, Inc.: C; ScienceBased Health: C; Sight Sciences, Inc.: C; STAAR Surgical: C; Surface: C; Tarsus: C,S; THEA: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S; Visus: C
    Sharon D Solomon MD NONE

    Subcommittee for: Cataract

    Chair Disclosure
    Nicole R Fram MD Alcon Laboratories, Inc.: C; Avellino Labs: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,L,SO; Glaukos Corporation: L; Johnson & Johnson Vision: L,C; LENSAR: C; Ocular Science: SO,C; Ocular Therapeutix: S; Orasis Pharmaceuticals: C,SO; OysterPoint: C; RxSight: L,C; Vital Tears: L; Zeiss: C,L,S
    Subcommittee Members
    Surendra Basti MBBS Johnson & Johnson Vision: C
    Sathish Srinivasan MBBS AcuFocus, Inc.: C; Alcon Laboratories, Inc.: C; DORC International, bv/Dutch Ophthalmic, USA: C; Medicontur: C; Scope Ophthalmics: C; THEA: L; Zeiss: C
    Subcommittee Reviewers
    Brandon Ayres MD Alcon Laboratories, Inc.: C,L; Allergan: C,L; Bausch+Lomb: L; Carl Zeiss Inc: C; CorneaGen: C; Dompe: C,L; Glaukos Corporation: C; New World Medical Inc: C; Novartis, Alcon Pharmaceuticals: C; Rayner Intraocular Lenses Ltd: C; Sun Ophthalmics: C,L
    Kourtney A Houser MD Abbvie: C; Avellino Labs: C; Bausch and Lomb: C; Novartis, Alcon Pharmaceuticals: C; RVL pharmaceuticals: C
    Sumitra S Khandelwal MD Alcon Laboratories, Inc.: C; Bausch + Lomb: C; Carl Zeiss Meditec: C; Dompe: C; Kala Pharmaceuticals, Inc.: C; Ocular Therapeutix: C
    Jeremy Z Kieval MD Alcon Laboratories, Inc.: C; Dompe: C; Johnson & Johnson: C,L; Kala: C,L; LENSAR: C; Novartis Pharma AG: C; Ocular Therapeutix: C; Sun Ophthalmics: C; Tarsus: C; Visus: C
    Steven M Naids MD Allergan, Inc.: C,L; Bausch + Lomb: L; Eyevance: C

    Subcommittee for: Cornea, External Disease

    Chair Disclosure
    Jessica B Ciralsky MD NONE
    Subcommittee Members
    Anat Galor MD Allergan: C; Astrozenica: C; Dompe: C; Novaliq: C; Novartis Pharma AG: C; Oculis: C; Oyster Point: C; Shire: C; Tarsus: C
    Elmer Y Tu MD Daiichi Sankyo: C; Dompe: C; GlaxoSmithKline: C; Oyster Point: C; Santen, Inc.: C
    Subcommittee Reviewers
    Vatinee Y Bunya MD NONE
    Asim V Farooq MD Ambrx: C; Amgen Inc: C; Daiichi-Sankyo: C; Eisai: C; GlaxoSmithKline: C; Sanofi: C; Seagen: C
    Christina R Prescott MD Johnson & Johnson Vision: C; Santen, Inc.: C
    Jennifer R Rose-Nussbaumer MD NONE
    Christopher S Sales MD Network Medical: P

    Subcommittee for: Glaucoma

    Chair Disclosure
    Paula Anne Newman-Casey MD NONE
    Subcommittee Members
    Brian C Samuels MD PhD Heidelberg Engineering: S
    John T Lind MD Abbvie: S; Heru: S; Nicox: S
    Subcommittee Reviewers
    Jenny Chen MD NONE
    Natasha Nayak Kolomeyer MD Abbvie: C,S; Aerie Pharmaceuticals, Inc.: S; Alimera Sciences, Inc.: C; Allergan, Inc.: C,S; Diopsys, Inc.: S; Equinox: S; GENENTECH: C; Glaukos Corporation: S; Guardion Health Sciences: S; Nicox: S; Olleyes: S; Regeneron Pharmaceuticals, Inc.: C; Santen: S
    Ahmara G Ross MD Gene Therapy for Ocular Disorders (Patent Number 16/607,834, 2019): P; Gyroscope Therapeutics: C,I; Noveome: C,P,S
    Catherine Q Sun MD NONE
    Luis E Vazquez MD NONE

    Subcommittee for: Neuro-Ophthalmology, Electronic Health Records/Information Technology, Ethics, General Medical, Global Ophthalmology, Medical Education, Ophthalmic History, Vision Rehabilitation and Wellness

    Chair Disclosure
    Andrew G Lee MD Horizon: C
    Subcommittee Members
    John J Chen MD PHD Horizon: C; Roche Diagnostics: C; UCB: C
    Julie Falardeau MD NONE
    Subcommittee Reviewers
    Nagham Al-Zubidi MD NONE
    Shauna E Berry DO NONE
    Courtney E Francis MD NONE
    Y Joyce Liao MD PhD AmMaxBio: C
    Claudia Maria Prospero Ponce MD NONE

    Subcommittee for: Ocular Pathology, Oncology and Oculoplastics, Orbit

    Chair Disclosure
    Jonathan W Kim MD NONE
    Subcommittee Members
    Sara T Wester MD Horizon Therapeutics: C; immunovant: C; Vasaragen: C
    Michael K Yoon MD Horizon: US
    Subcommittee Reviewers
    Malena M Amato MD NONE
    Anne Barmettler MD NONE
    Steven M Couch MD NONE
    Catherine J Hwang MD NONE
    Kenya M Williams MD NONE

    Subcommittee for: Pediatric Ophthalmology, Strabismus

    Chair Disclosure
    Martha P Schatz MD None
    Subcommittee Members
    Stacy L Pineles MD Asteroid 3D: S; fitz frames: C; horizon surgical: PS
    Federico G Velez MD Luminopia: S; Nevakar: C; Novartis: C,S; Viridian: S
    Subcommittee Reviewers
    Sean P Donahue MD PhD Gensight: C; Olleyes: C,PS
    Judith E Gurland MD NONE
    Tina Rutar MD Sydnexis: S,SO,C
    Ujwala Saboo MD NONE
    Mitchell B Strominger MD NONE

    Subcommittee for: Refractive Surgery and Optics, Refraction, Contact Lenses

    Chair Disclosure
    Elizabeth Yeu MD Advanced Vision Group: C; Alcon Laboratories, Inc.: C,L; Allergan, Inc.: C,L; Aurion: C; Bausch + Lomb: C; Bio-Tissue, Inc.: C,L; BlephEX, LLC: C; Bruder Healthcare Company: C; BVI: C; Carl Zeiss Meditec: C,L; CorneaGen: C; Dompe: C; Expert Opinion: C; Glaukos Corporation: C,L; Johnson & Johnson Vision: C,L; Kala Pharmaceuticals, Inc.: C,S; Katena Products, Inc: C; LENSAR: C; Melt: C; Novartis Pharma AG: C; OCuSOFT, Inc.: C; ScienceBased Health: C; Sight Sciences, Inc.: C; STAAR Surgical: C; Surface: C; Tarsus: C,S; THEA: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S; Visus: C
    Subcommittee Members
    Edward E Manche MD Alcon Laboratories, Inc.: S; Allergan: S; Averdro: C,S; Best Doctors, Inc.: C; Carl Zeiss Inc: C,S; Guidepoint: C; Johnson & Johnson Vision: C,S; KKR: C; Novartis Pharma AG: S; Placid0: PS,SO; Presbia, Inc.: S; RxSight: US; VacuSite: P,PS
    J Bradley Randleman MD NONE
    Subcommittee Reviewers
    Kathryn Masselam Hatch MD Alderya Therapeutics, Inc.: C; Carl Zeiss Meditec: C; cxlo: C; Glaukos Corporation: C,US; Johnson & Johnson Vision: C; Kala Pharmaceuticals, Inc.: C; Sun Ophthalmics: C
    Brad E Kligman MD Dompe: S
    Brian M Shafer MD Alcon Laboratories, Inc.: C; Allergan, Inc.: L; Equinox: C
    Denise M Visco MD Bausch + Lomb: C; Bruder Healthcare Company: C; Carl Zeiss Inc: C,L; Cassini USA, Inc.: C; LENSAR: C,L; Omeros: C,L; Oyster Point Pharma: C; Sun Pharmaceuticals: C,L
    Dagny C Zhu MD Alcon Laboratories, Inc.: C,S; Allergan: L; Johnson & Johnson Vision: C; LENSAR: C

    Subcommittee for: Retina, Vitreous and Uveitis, Intraocular Inflammation

    Chair Disclosure
    Sharon D Solomon MD NONE
    Subcommittee Members
    Anita Agarwal MD NONE
    Sunir J Garg MD FACS Allergan, Inc.: C; Apellis Pharmaceuticals, Inc.: S; Bausch+Lomb: C; Boehringer Ingelheim: C,S; Coherus: C; Johnson & Johnson: C; Kodiak: S; Merck Manual: C; NGM Bio: S; Regeneron Pharmaceuticals, Inc.: S
    Subcommittee Reviewers
    Mark Philip Breazzano MD NONE
    Roomasa Channa MD NONE
    Jay K Chhablani MBBS Abbvie: L; Allergan, Inc.: L; Novartis Pharma AG: C; Salutaris: C
    Yannis Mantas Paulus MD Hedgefog Research Inc: C; IRIDEX: C; MediBeacon: C; PhotoSonoX LLC: PS,EO,P
    Alice Yang Zhang MD NONE
    Thomas A Albini MD Adverum Biotechnologies: C; Applied Genetic Technologies Corporation: C; Bausch+Lomb: C; Beaver Visitec: C; Clearside: C; Eyepoint Pharmaceuticals, Inc.: C; GENENTECH: C; Mallinckrodt: C; Novartis, Alcon Pharmaceuticals: C; RegenexBio: C
    Bryn M Burkholder MD NONE
    John A Gonzales MD UCSF AutoImmunoprofiler: S
    Jaclyn L Kovach MD Novartis Pharma AG: L; Regeneron Pharmaceuticals, Inc.: L
    Jennifer E Thorne MD PhD AbbVie: C; ClearView: C; Gilead Sciences: C; Guidepoint: C; Roche Diagnostics: C; Tarsier Pharma: C,SO

    Special Projects Committee

    The Special Projects Committee is responsible for developing programming and formats that cross subspecialties, as well as complement those that are submitted by members or societies.

    Associate Secretary Disclosure
    Carolyn K Pan MD NONE
    Committee Members
    John J DeStafeno MD Sun Ophthalmics: L
    Laura B Enyedi MD Nevakar: C; novartis: C; Tarsus: C
    Collin M McClelland MD Horizon Therapeutics: C
    Beeran B Meghpara MD Allergan, Inc.: C,L; Carl Zeiss Meditec: C; CorneaGen: C; Dompe: L,C; Eyevance Pharmaceuticals: C,L; Glaukos Corporation: C; Johnson & Johnson Vision: C; Kala Pharmaceuticals, Inc.: L,C; Oculus, Inc.: C; Sight Sciences, Inc.: C; Sun Ophthalmics: C,L; Tarsus: C; W.L Gore & Associates: C
    Rachel K Sobel MD Guidepoint: C
    Kateki Vinod MD NONE

    Skills Transfer Advisory Committee

    The Skills Transfer Advisory Committee is responsible for selecting the Skills Transfer courses and labs.

    Associate Secretary Disclosure
    Michael L Savitt MD NONE
    Advisory Members
    Brock K Bakewell MD AcuFocus, Inc.: S; Johnson & Johnson Vision: S
    Cat Burkat MD FACS NONE
    Clara C Chan MD Abbvie: C,L; Aequus Pharmaceuticals: C; Allergan, Inc.: C,L,S; Daichii: C; Dompe: C; Johnson & Johnson Vision: C,US; Labtician Ophthalmics, Inc.: L; Novartis Pharma AG: C,S; Pfizer, Inc.: US; Santen, Inc.: C; Sun Ophthalmics: C; THEA: C,L; zeiss: C
    Brian A Francis MD Aerie Pharmaceuticals, Inc.: C,L; Alcon Laboratories, Inc.: C,S; Allergan, Inc.: C,S; Beaver-Visitec International, Inc.: C; Greybug: C; IRIDEX: C; Istar: C; MicroSurgical Technology: C
    Anjali Tannan MD NONE
    Keye L Wong MD NONE

    Subspecialty Day Advisory Committee

    Associate Secretary Disclosure
    R Michael Siatkowski MD NONE
    Advisory Members
    Bonnie An Henderson MD Alcon Laboratories, Inc.: C; Allergan, Inc.: C; Horizon: C
    Michael S Lee MD horizon: US; panbela: C; Pfizer, Inc.: US; springer: P; uptodate: P
    Jennifer Irene Lim MD Adverum Biotechnologies: S; Alderya Therapeutics, Inc.: S; Allergan, Inc.: C; Aura Biosciences: C; Chengdu Kanghong: S; Cognition Therapeutics: C; CRC Press/ Taylor and Francis: P; Eyenuk: C; GENENTECH: C,S,L; Greybug: S; Iveric Bio: C; JAMA Ophthalmology Editorial Board: C; Luxa: C; NGM: S; Novartis Pharma AG: C; Opthea: C; Quark: C; Regeneron Pharmaceuticals, Inc.: C,S; Santen, Inc.: C; Stealth: S; Unity: C; Viridian: C
    Shahzad I Mian MD Andover Eye Associates: S; Kowa American Corporation: S; Novartis: S; Vision care: S
    Jody R Piltz MD Aerie Pharmaceuticals, Inc.: C,L

    Subspecialty Day

    Cornea

    Program Directors Disclosure
    Vishal Jhanji MD NONE
    Sonal S Tuli MD NONE
    Christina Prescott MD Johnson & Johnson Vision: C; Santen, Inc.: C
    Program Planning Group
    Vishal Jhanji MD NONE
    Sonal S Tuli MD NONE
    Christina Prescott MD Johnson & Johnson Vision: C; Santen, Inc.: C

    Glaucoma

    Program Directors Disclosure
    Kelly Walton Muir MD NONE
    Teresa C Chen MD NONE
    Program Planning Group
    Robert T. Chang, MD Aerie Pharmaceuticals, Inc.: C; Alcon Laboratories, Inc.: C; Equinox: C; Genentech: C,S; Ocular Therapeutix: C; Omeros Corp.: C
    Babak Eliassi-Rad, MD NONE
    Ronald Leigh Fellman MD OCS NONE
    Christopher A. Girkin, MD, MSPH Amydis, Inc.: C,SO; Heidelberg Engineering: C,S; Topcon Medical Systems, Inc.: C,S
    Lily T. Im, MD NONE
    Robert J. Noecker, MD, MBA AbbVie: C,L; Alcon Laboratories, Inc.: C,L; Bausch + Lomb: C,L; Beaver-Visitec International, Inc.: C; Glaukos Corp.: C,S; Iridex: C,L; New World Medical, Inc.: L,C; Ocular Therapeutix: C,SO; Santen, Inc.: C; Sight Sciences, Inc.: C,SO,L; Thea: C
    Manjool M. Shah, MD Allergan: C; Glaukos Corp.: C; Ivantis: C; Katena Products, Inc.: C; ONL Therapeutics: C
    Ramya N. Swamy, MD, MPH NONE
    Luis E. Vazquez, MD, PhD New World Medical, Inc.: L

    Oculofacial Plastic Surgery

    Program Directors Disclosure
    Thomas Edward Johnson MD NONE
    Cat Burkat MD FACS NONE
    Program Planning Group
    Thomas Edward Johnson MD NONE
    Cat Burkat MD FACS NONE

    Pediatric Ophthalmology

    Program Directors Disclosure
    David K. Wallace, MD MPH NONE
    David G. Morrison, MD NONE
    Program Planning Group
    Robert A. Clark, MD NONE
    David K. Coats, MD NONE
    Sergul A. Erzurum, MD NONE
    Sharon F. Freedman, MD Qlaris Bio: C
    Nandini G. Gandhi, MD NONE
    Amy K. Hutchinson, MD NONE
    David G. Morrison, MD NONE
    Deborah K. VanderVeen, MD Ocular Therapeutix: S
    David K Wallace MD MPH NONE

    Refractive Surgery

    Program Directors Disclosure
    Deepinder K Dhaliwal MD Allergan, Inc.: C; Glaukos: S; Haag-Streit Group: C; Johnson & Johnson: C; Kowa American Corporation: S; Lenz Therapeutics: C; Novartis: C,S; Noveome: S; Ocular Therapeutix: C,L; STAAR Surgical: L; TearSolutions: C; Trefoil: C
    Jodhbir S Mehta MBBS NONE
    Program Planning Group
    Renato Ambrosio, Jr., MD Alcon Laboratories, Inc.: C; Allergan: L; Carl Zeiss, Inc.: L; Essilor Instruments: L; Genom: C,L; Mediphacos: L; Oculus, Inc.: C
    J. Burkhard Dick, MD AcuFocus, Inc.: C,SO; Bausch + Lomb: L; EuroEyes: C; Johnson & Johnson Vision: C; Morcher GmbH: P; Oculus Surgical, Inc.: P; RxSight Inc.: C
    Deepinder K Dhaliwal MD Allergan, Inc.: C; Glaukos: S; Haag-Streit Group: C; Johnson & Johnson: C; Kowa American Corporation: S; Lenz Therapeutics: C; Novartis: C,S; Noveome: S; Ocular Therapeutix: C,L; STAAR Surgical: L; TearSolutions: C; Trefoil: C
    Nicole Fram, MD Alcon Laboratories, Inc.: C; Avellino Labs: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,L,SO; Glaukos Corp.: L; Johnson & Johnson Vision: L,C; Lensar: C; Ocular Science: SO,C; Ocular Therapeutix: S; Orasis Pharmaceuticals: C,SO; OysterPoint: C; RxSight: L,C; Vital Tears: L; Zeiss: C,L,S
    Bonnie An Henderson, MD Alcon Laboratories, Inc.: C; Allergan, Inc.: C; Horizon: C
    Jodhbir S Mehta MBBS NONE
    J. Bradley Randleman, MD NONE

    Retina

    Program Directors Disclosure
    Srinivas R Sadda MD 4DMT: C; Alexion: C; Allergan: C; Amgen Inc: C; Apellis Pharmaceuticals, Inc.: C; Astellas: C; Bayer Healthcare Pharmaceuticals: C; Carl Zeiss Meditec: C,L,S; Centervue: C; GENENTECH: C; Gyroscope: C; Heidelberg Engineering: C,L,S; Iveric bio: C; Jannsen: C; Nanoscope: C; Nidek: L; Novartis Pharma AG: C,L; Optos, Inc.: C; oxurion: C; Pfizer, Inc.: C; Regeneron Pharmaceuticals, Inc.: C; Topcon Medical Systems Inc.: L
    Timothy G Murray MD MBA Alcon Laboratories, Inc.: C; FDA: C
    Program Planning Group
    Sophie J. Bakri, MD AbbVie: C; Adverum: C; Alimera Sciences, Inc.: C; Allergan: C; Apellis Pharmaceuticals, Inc.: C; Eyepoint: C; Genentech: C; Ilumen: C; Iveric Bio: C; Kala Pharmaceuticals, Inc.: C; Novartis; Alcon Pharmaceuticals: C; Outlook Therapeutics: C; Pixium: C; Regenxbio: C,S; ReVana: SO; Roche: C; VoxelCloud: SO; Zeiss: C
    Barbara Ann Blodi, MD NONE
    Timothy G Murray MD MBA Alcon Laboratories, Inc.: C; FDA: C
    Srinivas R Sadda MD 4DMT: C; Alexion: C; Allergan: C; Amgen Inc: C; Apellis Pharmaceuticals, Inc.: C; Astellas: C; Bayer Healthcare Pharmaceuticals: C; Carl Zeiss Meditec: C,L,S; Centervue: C; GENENTECH: C; Gyroscope: C; Heidelberg Engineering: C,L,S; Iveric bio: C; Jannsen: C; Nanoscope: C; Nidek: L; Novartis Pharma AG: C,L; Optos, Inc.: C; oxurion: C; Pfizer, Inc.: C; Regeneron Pharmaceuticals, Inc.: C; Topcon Medical Systems Inc.: L

    Uveitis

    Program Directors Disclosure
    Russell W Read MD PhD NONE
    Lucia Sobrin MD NONE
    Program Planning Group
    Wendy M. Smith, MD NONE
    Kathryn L. Pepple, MD, PhD NONE
    Edmund Tsui, MD Cylite Pty, Ltd.: S; EyePoint Pharmaceuticals: C; Kowa Company, Ltd.: C,S; Pfizer, Inc.: S
    Stephanie M. Llop Santiago, MD NONE
    Ann-Marie Lobo, MD Alcon Laboratories, Inc.: C; Bausch + Lomb: C; Neolight: C; Phoenix Technology Group: C; Siloam Vision: C

    AAOE Content Committee

    The AAOE Annual Meeting Program Committee is responsible for selecting the AAOE Instruction Courses, Coding Sessions and the Practice Management Master Classes.

    Chair Disclosure
    Natalie M Loyacano COMT ROUB OSA OCSR (F)ATPO None
    Committee Members
    Stephanie Collins Mangham MBA COA OCSR Regeneron Pharmaceuticals, Inc.: C,L
    Tori Elkins COT MBA NONE
    Brett D Gerwin MD NONE
    Sondra Hoffman COE CPE CMPE HRM Hoffman Consulting Group: EE
    Anthony Pruett Johnson MD FACS NONE
    Bansari Mehta MHA NONE
    Christine M McDonald COE COA ROUB OSC CTC OCS NONE
    Heather Modjesky COE NONE
    Savory A Turman COMT NONE

    Academy Staff

    Name Disclosure
    Debra Rosencrance NONE
    Melanie Rafaty NONE
    Sangeeta Fernandes NONE
    Ann L'Estrange NONE
    Susan Oslar NONE
    Elizabeth Washburn NONE
    Licia Wells NONE
    Julia Fennell NONE
    Sadie Peckens NONE